NYSE:NVO - Novo Nordisk A/S Stock Price, Forecast & News

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVO shares have decreased by 2.0% and is now trading at $56.73. View which stocks have been mosted impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Novo Nordisk A/S.

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Friday, May 1st 2020. View our earnings forecast for Novo Nordisk A/S.

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings data on Wednesday, February, 5th. The company reported $0.55 EPS for the quarter, hitting the consensus estimate of $0.55. The business earned $4.80 billion during the quarter, compared to analysts' expectations of $4.83 billion. Novo Nordisk A/S had a net margin of 31.95% and a return on equity of 73.70%. View Novo Nordisk A/S's earnings history.

Novo Nordisk A/S announced a semi-annual dividend on Friday, February 7th. Stockholders of record on Monday, March 30th will be given a dividend of $0.7874 per share on Tuesday, April 7th. This represents a yield of 1.4%. The ex-dividend date is Friday, March 27th. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.32. View Novo Nordisk A/S's dividend history.

Novo Nordisk A/S updated its FY 2020 IntraDay earnings guidance on Wednesday, February, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $18.852-19.401 billion, compared to the consensus revenue estimate of $18.74 billion.

9 brokerages have issued twelve-month target prices for Novo Nordisk A/S's shares. Their forecasts range from $51.85 to $400.00. On average, they anticipate Novo Nordisk A/S's stock price to reach $214.82 in the next year. This suggests a possible upside of 278.7% from the stock's current price. View analysts' price targets for Novo Nordisk A/S.

Media headlines about NVO stock have trended somewhat positive this week, according to InfoTrie. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novo Nordisk A/S earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutNovo Nordisk A/S.

Novo Nordisk A/S saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 5,108,900 shares, an increase of 9.9% from the February 27th total of 4,650,000 shares. Based on an average daily trading volume, of 1,500,000 shares, the days-to-cover ratio is presently 3.4 days. Approximately 0.4% of the shares of the stock are sold short. View Novo Nordisk A/S's Current Options Chain.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Vertex Pharmaceuticals (VRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), QUALCOMM (QCOM), Starbucks (SBUX), Alibaba Group (BABA) and Walt Disney (DIS).

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.11%), Loomis Sayles & Co. L P (0.92%), Bank of America Corp DE (0.48%), State Street Corp (0.19%), Everett Harris & Co. CA (0.13%) and Sustainable Growth Advisers LP (0.11%). View institutional ownership trends for Novo Nordisk A/S.

NVO stock was sold by a variety of institutional investors in the last quarter, including Sustainable Growth Advisers LP, Bank of America Corp DE, State Street Corp, NorthCoast Asset Management LLC, Credit Suisse AG, Alyeska Investment Group L.P., Hikari Power Ltd, and Boston Partners. View insider buying and selling activity for Novo Nordisk A/S.

NVO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, First Trust Advisors LP, Loomis Sayles & Co. L P, Capital International Investors, Amundi Pioneer Asset Management Inc., Bain Capital Public Equity Management II LLC, Connor Clark & Lunn Investment Management Ltd., and Beacon Investment Advisory Services Inc.. View insider buying and selling activity for Novo Nordisk A/S.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVO stock can currently be purchased for approximately $56.73.

Novo Nordisk A/S has a market capitalization of $134.34 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis. Novo Nordisk A/S employs 43,258 workers across the globe. View additional information about Novo Nordisk A/S.

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]